Fulcrum Therapeutics Stock Today
| FULC Stock | USD 7.90 0.01 0.13% |
PerformanceSolid
| Odds Of DistressLow
|
Fulcrum Therapeutics is trading at 7.90 as of the 24th of July 2025, a 0.13 percent decrease since the beginning of the trading day. The stock's open price was 7.91. Fulcrum Therapeutics has only a 7 % chance of going through financial distress over the next few years and had a solid performance during the last 90 days. The performance scores are derived for the period starting the 25th of April 2025 and ending today, the 24th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of July 2019 | Category Healthcare | Classification Health Care |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. The company has 53.98 M outstanding shares of which 5.64 M shares are currently shorted by private and institutional investors with about 11.02 trading days to cover. More on Fulcrum Therapeutics
Moving together with Fulcrum Stock
| 0.66 | VRDN | Viridian Therapeutics | PairCorr |
| 0.79 | VTYX | Ventyx Biosciences | PairCorr |
| 0.76 | PFE | Pfizer Inc | PairCorr |
| 0.73 | MRVI | Maravai Lifesciences | PairCorr |
| 0.64 | NUVL | Nuvalent | PairCorr |
Moving against Fulcrum Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Fulcrum Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Alexander Sapir | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsFulcrum Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Fulcrum Therapeutics' financial leverage. It provides some insight into what part of Fulcrum Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fulcrum Therapeutics (FULC) is traded on NASDAQ Exchange in USA. It is located in 26 Landsdowne Street, Cambridge, MA, United States, 02139 and employs 45 people. Fulcrum Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 426.98 M. Fulcrum Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 53.98 M outstanding shares of which 5.64 M shares are currently shorted by private and institutional investors with about 11.02 trading days to cover.
Fulcrum Therapeutics currently holds about 221.79 M in cash with (2.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26.
Check Fulcrum Therapeutics Probability Of Bankruptcy
Ownership AllocationFulcrum Therapeutics holds a total of 53.98 Million outstanding shares. The majority of Fulcrum Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Fulcrum Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Fulcrum Therapeutics. Please pay attention to any change in the institutional holdings of Fulcrum Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Fulcrum Ownership Details
Fulcrum Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Exome Asset Management Llc | 2025-03-31 | 689.1 K | |
| Northern Trust Corp | 2025-03-31 | 640.9 K | |
| D. E. Shaw & Co Lp | 2025-03-31 | 580.7 K | |
| Adar1 Capital Management Llc | 2025-03-31 | 490.5 K | |
| Goldman Sachs Group Inc | 2025-03-31 | 402.6 K | |
| Renaissance Technologies Corp | 2025-03-31 | 401.1 K | |
| Charles Schwab Investment Management Inc | 2025-03-31 | 381.4 K | |
| Citadel Advisors Llc | 2025-03-31 | 374.3 K | |
| Acadian Asset Management Llc | 2025-03-31 | 344.6 K | |
| Ra Capital Management, Llc | 2025-03-31 | 10.2 M | |
| Tcg Crossover Management, Llc | 2025-03-31 | 5.2 M |
Fulcrum Therapeutics Historical Income Statement
Fulcrum Stock Against Markets
Fulcrum Therapeutics Corporate Management
| Rudolf MD | Founder | Profile | |
| CPA CMA | Chief Officer | Profile | |
| Jeffrey Jacobs | Chief Officer | Profile | |
| Mel Hayes | Executive Experience | Profile | |
| Paul Bruno | Senior Development | Profile | |
| Bryan Stuart | CEO Pres | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.